DexCom Inc.
DXCM.US | Manufacture of medical and dental instruments and supplies
DexCom, Inc. is a medical device company focused on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for people with diabetes. Their primary product is the Dexcom G6 and G7 CGM systems, which consist of a small, wearable sensor that continuously measures ...Show More
Better Health for All
40
Dexcom's core products, continuous glucose monitoring (CGM) systems, deliver significant health benefits. The Dexcom Community Glucose Monitoring Project showed a mean HbA1c reduction of 2.4% (from 9.4% to 7.1%) for participants
1
. The use of the Dexcom G6 CGM system was associated with a significant reduction in diabetes-related emergency department visits and inpatient hospitalizations
2
, decreasing average per-person per-month hospitalization costs by $341
3
. All of the company's products are focused on improving health outcomes for people with diabetes, with no evidence of negative health impacts. This entire product line emphasizes disease prevention by helping manage diabetes to prevent acute events and long-term complications. As a medical device company, its operations are not applicable to pharmaceutical patent flexibility, nutrition and food safety, or addiction mitigation.
Fair Money & Economic Opportunity
0
DexCom Inc. is a medical device company, not a financial institution. As such, the company does not offer lending, deposit, or other financial services to consumers, nor does it generate customer financial data. Consequently, all KPIs under the 'Fair Money & Economic Opportunity' value are not applicable to its core business, resulting in a score of 0 for each. Despite this, DexCom has undertaken initiatives to enhance access to its medical devices for underserved populations. In August 2024, it launched Dexcom Stelo, an over-the-counter continuous glucose monitor priced at $99 for two 15-day sensors, targeting individuals with type 2 diabetes not requiring insulin and those managing prediabetes.
1
In June 2024, Dexcom ONE secured full national reimbursement for 100,000 individuals in France with type 2 diabetes on basal insulin.
2
The Community Glucose Monitoring Project provides CGM systems to uninsured adults with type 2 diabetes, demonstrating a reduction in mean A1C levels by 2.4%, from 9.4% to 7.1%.
3
In September 2021, the Dexcom G6 CGM System was included in the Non-Insured Health Benefits program for First Nations and Inuit children and adolescents.
4
The company faced a class-action lawsuit in September 2024 alleging securities fraud and misleading financial reporting.
5
Fair Pay & Worker Respect
-20
Dexcom had one substantiated labor law violation in the past three years, specifically a WARN Act notice shortfall in June 2024 for a mass layoff of 535 employees in San Diego, where the required 60-day notice was not provided.
1
The company maintains a Compliance Helpline, hosted by a third-party, for employees to confidentially report policy violations or ethical concerns, which are promptly investigated.
2
Fair Trade & Ethical Sourcing
0
While policies like a Supplier Code of Conduct and a Human Rights Statement prohibiting child and forced labor are mentioned, and the company addresses conflict minerals, no concrete percentages, frequencies, or incident numbers are provided for any of the defined KPIs.
1
2
Honest & Fair Business
0
DexCom Inc. is facing a class-action lawsuit filed in July 2024, alleging the company misled investors about financial performance and growth prospects, including false information on customer acquisition and distribution channels
1
. The company has a Compliance Helpline managed by a third-party for confidential reporting of potential policy violations
2
and maintains a strict non-retaliation policy for good-faith reporters
3
. Additionally, DexCom has implemented an Anti-Bribery Policy as part of its governance documents
4
.
Kind to Animals
-40
Dexcom conducts necessary preclinical studies that involve animal testing to assess product safety, focusing on tissue biocompatibility and toxicity testing.
1
The company's policy states a commitment to conducting all animal research in a responsible, humane, and ethical manner.
2
,
3
maintaining high standards of animal care and welfare consistent with or exceeding those required by law.
4
,
5
No War, No Weapons
10
DexCom, a medical device company, explicitly states its mission is to provide healthcare solutions without military involvement. Its continuous glucose monitoring (CGM) systems are available to military members through TRICARE
1
and to veterans through VA pharmacies
2
, but these applications are strictly for personal healthcare and involve no weapons. The company's products are developed without any weapons involvement or military applications beyond personal healthcare, indicating no dual-use technology and zero exposure to any weapons. The company has no defense assets to divest. Its Supplier Code of Conduct emphasizes legal compliance and ethical business practices
3
, including a commitment to eradicating human trafficking within its supply chain
4
, and its mission implies no military suppliers.
Planet-Friendly Business
0
Dexcom's total Scope 1, 2, and 3 greenhouse gas emissions for 2023 were 808.56 tCO2e, comprising 15.81 tCO2e for Scope 1, 67.64 tCO2e for Scope 2, and 725.11 tCO2e for Scope 3.
1
The company achieved a 17.6% reduction in greenhouse gas emissions across its global operations in 2022.
2
Dexcom published its inaugural greenhouse gas emissions disclosure in its annual sustainability report.
3
The company also reported a 22% reduction in water consumption during production.
4
The G7 continuous glucose monitoring system reduces disposable components by 42%, preventing approximately 3.2 million device components from entering waste streams annually.
5
Dexcom committed to reducing carbon emissions by 30% by 2025
6
and projects a 26% reduction in carbon emissions in the UK over the next five years, aiming for 599 tCO2e by 2030.
7
Respect for Cultures & Communities
0
Dexcom has no reported cultural appropriation incidents.
1
The company's operations do not involve activities that would typically require Free, Prior and Informed Consent (FPIC) processes, nor are there reported disruptions to cultural or heritage sites.
2
No specific cultural incident response framework is reported as applicable.
3
Safe & Smart Tech
10
DexCom's Information Security Management System is certified to ISO/IEC 27001.
1
Their cybersecurity programs comply with relevant regulations.
2
The company provides employee training on cyber threats and incident response.
3
Data protection is enforced through encryption.
4
Zero Waste & Sustainable Products
-30
Dexcom has reduced the material use of its G7 sensor by 60%.
1
The company also reduced the plastic used in its applicator by over 20%.
2
Additionally, an electronic waste recycling program successfully recycled 18,000 pounds of waste.
3